CRISPR Therapeutics (NASDAQ:CRSP) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.
Analyst Ratings
This is a breakdown of recent ratings and price targets for CRISPR Therapeutics and QIAGEN, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
CRISPR Therapeutics | 2 | 4 | 12 | 0 | 2.56 |
QIAGEN | 1 | 6 | 9 | 0 | 2.50 |
CRISPR Therapeutics presently has a consensus price target of $150.8125, indicating a potential upside of 33.51%. QIAGEN has a consensus price target of $56.3689, indicating a potential upside of 18.67%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe CRISPR Therapeutics is more favorable than QIAGEN.
Volatility & Risk
CRISPR Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
Profitability
This table compares CRISPR Therapeutics and QIAGEN's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
CRISPR Therapeutics | -273.10% | -20.72% | -18.35% |
QIAGEN | 11.18% | 17.51% | 8.44% |
Earnings & Valuation
This table compares CRISPR Therapeutics and QIAGEN's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
CRISPR Therapeutics | $289.59 million | 29.42 | $66.86 million | $1.17 | 96.55 |
QIAGEN | $1.53 billion | 7.09 | $-41,460,000.00 | $1.43 | 33.22 |
CRISPR Therapeutics has higher earnings, but lower revenue than QIAGEN. QIAGEN is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
66.4% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 43.6% of QIAGEN shares are owned by institutional investors. 17.1% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 9.0% of QIAGEN shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
CRISPR Therapeutics beats QIAGEN on 8 of the 14 factors compared between the two stocks.